Price
No data yet.
Social Signal Score
Analyst Ratings
7 analystsRevenue
$3.0K-99.76%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Lynn Seely
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 161
- Beta
- -0.07
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- -8.82
Financials
Revenue
$3.0K-99.8%Net Income
$-45.53MEBITDA
$-43.48MFree Cash Flow
$-34.63MEPS (diluted)
$-1.86Shares Outstanding (diluted)
24.44M+98.2%Operating Expenses
$50.20MCash & Debt
$177.11MReturn of Capital
$0.00Revenue by Segment (annual)
$36.0KQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $36.0K | $-274.45M | $-16.06 |
| 2024 | $61.0K | $-342.99M | $-1.31 |
| 2023 | $130.0K | $-234.63M | $-0.93 |
| 2022 | $84.68M | $-183.12M | $-0.74 |
| 2021 | $10.65M | $-250.22M | $-1.03 |
| 2020 | $7.76M | $-204.47M | $-0.84 |
| 2019 | $657.0K | $-129.38M | $-0.53 |
Valuation
LYELhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50-7.41%Social Signal Score
Mentions (6)
- Newszacks.com·6d ago·Neutral
Wall Street Analysts See a 148.25% Upside in Lyell Immunopharma (LYEL): Can the Stock Really Move This High? The average of price targets set by Wall Street analysts indicates a potential upside of 148.3% in Lyell Immunopharma (LYEL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
View source ↗ - Newsseekingalpha.com·17d ago·Positive
Lyell: Upgrade To 'Buy' On Ronde-Cel Advancement LBCL And $80 Million Funding Boost Lyell Immunopharma is upgraded to “Buy” as pivotal ronde-cel CAR-T programs advance in relapsed/refractory large B-cell lymphoma [r/r LBCL]. LYEL secured $80 million in private placement, extending cash runway into 2028 and supporting ongoing pivotal and phase 3 trials. Key catalysts include ASH 2026 data updates for ronde-cel in 2nd/3rd-line r/r LBCL and phase 1/2 data for LYL273 in metastatic colorectal cancer.
View source ↗ - Newsglobenewswire.com·18d ago·Neutral
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2026 SOUTH SAN FRANCISCO, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today reported financial results and business highlights for the third quarter ended September 30, 2026.
View source ↗ - Newsglobenewswire.com·18d ago·Negative
…Private Placement to Advance Ronde-Cel Toward Planned BLA Submission SOUTH SAN FRANCISCO, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today announced that it has entered into a securities purchase agreement for a private placement of approximately $80 million of its common stock. The investors include ARCH Venture …
View source ↗ - Newsglobenewswire.com·20d ago·Negative
Lyell Immunopharma To Participate in November Investor Events SOUTH SAN FRANCISCO, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today announced that members of its senior management team will participate in the following investor events: Goldman Sachs' RxChange Series: Framing Lyell's next-generation lymphoma CAR-T …
View source ↗ - Newszacks.com·40d ago·Neutral
Down 27% in 4 Weeks, Here's Why Lyell Immunopharma (LYEL) Looks Ripe for a Turnaround Lyell Immunopharma (LYEL) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
View source ↗
Earnings
Thu, Mar 11(in 4 months)
Consensus estimate $-1.88 per share
Typical surprise +2.5% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Nov 4$-1.86 vs $-1.91beat
- Thu, Aug 6$-1.92 vs $-1.90miss
- Wed, May 6$-1.10 vs $-2.78beat
- Thu, Mar 12$-7.68 vs $-2.15miss
- Wed, Nov 12$-2.13 vs $-2.81beat
- Tue, Aug 12$-2.89 vs $-3.80beat
Estimates and results for LYEL via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by LYEL officers and directors.
- Bought
- $75.0m
- Sold
- $761k
4 trades
45 trades
- Lee Gary K.sold
- Hill Stephen J.sold
- Seely Lynnsold
- Bulis Veronica Sanchezsold
- Arch Venture Partners Ix, Llcbought
- Arch Venture Fund Xiii, L.p.bought
- Aguirre Jarrad Mattieusold
- Shook Davidsold
51 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in LYEL.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
